PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
4.87%
Revenue growth at 50-75% of 3391.T's 7.92%. Martin Whitman would worry about competitiveness or product relevance.
12.17%
Gross profit growth above 1.5x 3391.T's 7.34%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
54.90%
EBIT growth 75-90% of 3391.T's 69.05%. Bill Ackman would push for cost reforms or better product mix to narrow the gap.
49.18%
Operating income growth at 50-75% of 3391.T's 69.04%. Martin Whitman would doubt the firm’s ability to compete efficiently.
14.74%
Net income growth under 50% of 3391.T's 1537.59%. Michael Burry would suspect the firm is falling well behind a key competitor.
14.74%
EPS growth under 50% of 3391.T's 1537.18%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
14.74%
Diluted EPS growth under 50% of 3391.T's 1532.39%. Michael Burry would worry about an eroding competitive position or excessive dilution.
-0.00%
Share reduction while 3391.T is at 0.03%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Reduced diluted shares while 3391.T is at 0.32%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-100.00%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
149.77%
Similar 10Y revenue/share CAGR to 3391.T's 144.31%. Walter Schloss might see both firms benefiting from the same long-term demand.
59.05%
5Y revenue/share CAGR above 1.5x 3391.T's 30.17%. David Dodd would look for consistent product or market expansions fueling outperformance.
38.14%
3Y revenue/share CAGR above 1.5x 3391.T's 15.77%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
199.81%
Net income/share CAGR above 1.5x 3391.T's 102.69% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
61.16%
5Y net income/share CAGR above 1.5x 3391.T's 2.23%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
30.34%
3Y net income/share CAGR above 1.5x 3391.T's 18.84%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
318.66%
10Y equity/share CAGR above 1.5x 3391.T's 134.09%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
81.97%
5Y equity/share CAGR above 1.5x 3391.T's 33.52%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
35.33%
3Y equity/share CAGR above 1.5x 3391.T's 10.68%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
3.30%
AR growth well above 3391.T's 6.12%. Michael Burry fears inflated revenue or higher default risk in the near future.
0.78%
We show growth while 3391.T is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
1.69%
Asset growth 1.25-1.5x 3391.T's 1.30%. Bruce Berkowitz sees if the firm's investments effectively outpace the competitor in future returns.
2.49%
BV/share growth above 1.5x 3391.T's 0.87%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-21.26%
We’re deleveraging while 3391.T stands at 6.55%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
5.14%
We expand SG&A while 3391.T cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.